Damor Data and BioMap Announce Strategic Collaboration to Accelerate Drug Discovery with Integrated Data and AI Algorithms

Leiphone reports that in May 2021, DaMo Data and BioMap signed a memorandum of understanding on strategic cooperation.

Both parties will fully leverage their respective strengths to conduct comprehensive ecosystem collaboration across all stages, including scientific research services, scientific research project design, industrial application of new technologies, and new product development and commercialization.

This collaboration is built upon Dammo Data’s specialized expertise in the pharmaceutical data sector and its long-term accumulation of technological and data resources. By leveraging BioMap’s biological computing engine—which encompasses cutting-edge omics detection and analysis technologies, a multi-omics integrated mining platform, an AI-driven drug design platform, and a high-throughput in vitro simulation and drug validation platform—and capitalizing on the advantages of utilizing artificial intelligence to empower the entire pipeline of new drug R&D, manufacturing, and regulatory submission, the partnership will comprehensively advance the deep integration of R&D collaboration and technological innovation.

Leiphone(WeChat Official Account: Leiphone)It is understood that BioMap is a leading biotechnology-driven life sciences platform company in China, spearheaded by Baidu founder Li Yanhong. Established by leveraging Baidu Ventures' years of global expansion, it is currently backed by RMB 10 billion in funding, operates a global business network, and maintains an investment portfolio of 50+ cutting-edge technologies.

Based on longitudinal, multi-omics, and multi-level analyses of large-scale clinical cohorts, BioMap explores biological mechanisms and regulatory patterns across multiple fields, including cancer, autoimmune diseases, and aging-related disorders.

Damo Data is dedicated to integrating artificial intelligence with multiple disciplines such as pharmaceutical sciences, chemistry, and biology, aiming to build an AI+ drug R&D data platform that leverages big data and AI technologies to empower pharmaceutical companies throughout their drug discovery and development processes.

The proprietary knowledge graph is structured around active pharmaceutical ingredients, targets, companies, and indications, covering over 30,000 small-molecule drugs and biologics globally across marketed, clinical application, and R&D stages. It encompasses comprehensive data spanning the entire R&D spectrum, including drug activity data, target information, clinical trials, regulatory registration and approval, consistency evaluations, commercialization and sales data, formulations and excipients, manufacturing process data, pharmacopoeias, drug labels and the Orange Book, guidelines and reports, patents, and scientific literature.

DaMo Data CEO Zhang Yu is highly optimistic about the practical application of the two companies in AI-driven drug discovery and development.

He believes that new technologies will deliver highly efficient solutions, which will in turn help unlock blue-ocean markets. “In this productivity revolution, DaMo is among the pioneering enterprises to effectively integrate pharmaceutical big data with AI algorithms, having thoroughly optimized its computational architecture and established a drug data iteration system at the engineering level. This strategic partnership has already provided preliminary validation of the feasibility and scalability of our technology.”

Original article by Leiphone. Unauthorized reproduction is strictly prohibited. For details, please seeReprint Guidelines。